PURPOSE: To investigate whether skip axillary metastases are really skip metastases or a continuation of level I micrometastases in invasive breast cancer, and to determine whether there are any factors predisposing to skip metastases. METHODS: We reviewed 568 consecutive patients with breast cancer who underwent complete axillary lymph node dissections (ALND) between January 1998 and December 2004. For patients with skip axillary lymph node metastases, resectioning and immunohistochemical staining of the remaining part of paraffin blocks from level I lymph nodes were done to determine whether there were any micrometastases in this group of lymph nodes. RESULTS: Skip axillary metastases were found in 27 (10%) of 268 patients with axillary lymph node metastases. Re-evaluation of the level I lymph nodes, both with thin sectioning and immunohistochemical staining, in the patients with axillary skip metastases revealed no micrometastases. No significant correlation was found between the demographic and histopathological variables of the patients with skip metastases and those with regular axillary metastases. CONCLUSIONS: These results suggest that skip axillary metastases are actual skip metastases, not a continuation of undetected level I micrometastases. Moreover, none of the clinical and histopathological measures of primary tumors are predictors of the presence of skip metastases.
PURPOSE: To investigate whether skip axillary metastases are really skip metastases or a continuation of level I micrometastases in invasive breast cancer, and to determine whether there are any factors predisposing to skip metastases. METHODS: We reviewed 568 consecutive patients with breast cancer who underwent complete axillary lymph node dissections (ALND) between January 1998 and December 2004. For patients with skip axillary lymph node metastases, resectioning and immunohistochemical staining of the remaining part of paraffin blocks from level I lymph nodes were done to determine whether there were any micrometastases in this group of lymph nodes. RESULTS:Skip axillary metastases were found in 27 (10%) of 268 patients with axillary lymph node metastases. Re-evaluation of the level I lymph nodes, both with thin sectioning and immunohistochemical staining, in the patients with axillary skip metastases revealed no micrometastases. No significant correlation was found between the demographic and histopathological variables of the patients with skip metastases and those with regular axillary metastases. CONCLUSIONS: These results suggest that skip axillary metastases are actual skip metastases, not a continuation of undetected level I micrometastases. Moreover, none of the clinical and histopathological measures of primary tumors are predictors of the presence of skip metastases.
Authors: L A Newman; K K Hunt; T Buchholz; H M Kuerer; G Vlastos; N Mirza; F C Ames; M I Ross; S E Singletary Journal: Am J Surg Date: 2000-10 Impact factor: 2.565
Authors: Marjolein L Smidt; Caroline M M Janssen; Deborah M Kuster; Erik D M Bruggink; Luc J A Strobbe Journal: Ann Surg Oncol Date: 2005-01 Impact factor: 5.344
Authors: Anees B Chagpar; Robert C Martin; Charles R Scoggins; David J Carlson; Alison L Laidley; Souzan E El-Eid; Terre Q McGlothin; Robert D Noyes; Phillip B Ley; Todd M Tuttle; Kelly M McMasters Journal: Surgery Date: 2005-07 Impact factor: 3.982
Authors: M Overgaard; P S Hansen; J Overgaard; C Rose; M Andersson; F Bach; M Kjaer; C C Gadeberg; H T Mouridsen; M B Jensen; K Zedeler Journal: N Engl J Med Date: 1997-10-02 Impact factor: 91.245
Authors: Igor Langer; Walter Richard Marti; Ulrich Guller; Holger Moch; Felix Harder; Daniel Oertli; Markus Zuber Journal: Ann Surg Date: 2005-01 Impact factor: 12.969
Authors: Till-Alexander Heusner; Sherko Kuemmel; Angela Koeninger; Monia E Hamami; Steffen Hahn; Anton Quinsten; Andreas Bockisch; Michael Forsting; Thomas Lauenstein; Gerald Antoch; Alexander Stahl Journal: Eur J Nucl Med Mol Imaging Date: 2010-03-04 Impact factor: 9.236
Authors: Zachary T Bennett; Qiang Feng; Justin A Bishop; Gang Huang; Baran D Sumer; Jinming Gao Journal: Theranostics Date: 2020-02-10 Impact factor: 11.556